Cadence Pharmaceuticals Inc.
Cadence Pharmaceuticals Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States. Founded in 2004, the company has made significant strides in developing innovative therapies, particularly in pain management and anaesthesia. Cadence is renowned for its flagship product, OFIRMEV, an intravenous formulation of acetaminophen, which has transformed pain relief protocols in hospitals.
With a focus on enhancing patient care, Cadence Pharmaceuticals has established a strong market position, recognised for its commitment to quality and efficacy. The company operates primarily in North America, with a growing presence in international markets. Cadence's dedication to research and development continues to drive its success, positioning it as a leader in the pharmaceutical landscape.
-5 vs industry average
Cadence Pharmaceuticals Inc.’s score of 33 is higher than 57% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Cadence Pharmaceuticals Inc.?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Reported emissions
No reported emissions data is available for Cadence Pharmaceuticals Inc. yet.
Cadence Pharmaceuticals Inc.'s reported carbon emissions
Cadence Pharmaceuticals Inc., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Mallinckrodt plc, which may influence its climate commitments and reporting practices.
As of now, Cadence Pharmaceuticals has not established any documented reduction targets or initiatives related to carbon emissions. This lack of specific targets suggests that the company may be in the early stages of developing a comprehensive climate strategy.
Given the context of its parent company, Mallinckrodt plc, it is important to note that emissions data and climate commitments may be cascaded from this higher-level organisation. However, no specific emissions data or reduction initiatives from Mallinckrodt plc have been detailed in the provided information.
In summary, while Cadence Pharmaceuticals Inc. does not currently report emissions or reduction targets, its relationship with Mallinckrodt plc may play a role in shaping its future climate commitments.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Cadence Pharmaceuticals Inc.’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Cadence Pharmaceuticals Inc. yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
Carbon Disclosure Project
Inherited from Mallinckrodt plc
The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisations
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project